FDA Clearance Tracker · P040024-S132
Restylane Injectable Gel
Last checked: Nov 20, 2026Latest source record: Dec 20, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 20, 2022
Approved
Time to decision
105 days
Received Sep 6, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the addition of lidocaine hydrochloride from a new manufacturing site of the lidocaine hydrochloride supplier.
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® ContourPMA supplement
P140029-S054 · Decided Mar 20, 2026 · 239 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.